Nautilus Biotechnology Stock Performance

NAUT Stock  USD 2.69  0.50  22.83%   
On a scale of 0 to 100, Nautilus Biotechnology holds a performance score of 7. The company secures a Beta (Market Risk) of -0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Nautilus Biotechnology are expected to decrease at a much lower rate. During the bear market, Nautilus Biotechnology is likely to outperform the market. Please check Nautilus Biotechnology's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Nautilus Biotechnology's current price movements will revert.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Nautilus Biotechnology are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Nautilus Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
22.83
Five Day Return
25.7
Year To Date Return
40.84
Ten Year Return
(74.23)
All Time Return
(74.23)
1
Acquisition by Anna Mowry of 5500 shares of Nautilus Biotechnology at 2.7499 subject to Rule 16b-3
11/18/2025
2
Nautilus Biotechnology Upgraded at Wall Street Zen
11/21/2025
3
Penny Stocks To Consider In December 2025
12/01/2025
4
Acquisition by Sujal Patel of 650000 shares of Nautilus Biotechnology at 2.0 subject to Rule 16b-3
12/05/2025
5
Nautilus Biotechnology Stock Price Up 0.5 percent - Heres What Happened - MarketBeat
12/09/2025
6
Why Nautilus Biotechnology Inc. stock remains on buy lists - 2025 Market WrapUp Community Consensus Picks - Blm Sonu Canavar
12/19/2025
7
Acquisition by Anna Mowry of 160000 shares of Nautilus Biotechnology at 2.0 subject to Rule 16b-3
12/22/2025
8
Nautilus Biotechnology, Inc. boasts of bullish insider sentiment with 33 percent ownership and they have been buying lately
12/29/2025
9
Whats the MACD signal for Nautilus Biotechnology Inc. - Earnings Recap Report AI Enhanced Trading Signals - mfd.ru
01/22/2026
10
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkins...
01/28/2026
11
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
02/05/2026
Begin Period Cash Flow20.4 M
Total Cashflows From Investing Activities66.2 M

Nautilus Biotechnology Relative Risk vs. Return Landscape

If you would invest  212.00  in Nautilus Biotechnology on November 20, 2025 and sell it today you would earn a total of  57.00  from holding Nautilus Biotechnology or generate 26.89% return on investment over 90 days. Nautilus Biotechnology is currently generating 0.5616% in daily expected returns and assumes 5.7851% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Nautilus, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Nautilus Biotechnology is expected to generate 7.64 times more return on investment than the market. However, the company is 7.64 times more volatile than its market benchmark. It trades about 0.1 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.18 per unit of risk.

Nautilus Biotechnology Target Price Odds to finish over Current Price

The tendency of Nautilus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.69 90 days 2.69 
near 1
Based on a normal probability distribution, the odds of Nautilus Biotechnology to move above the current price in 90 days from now is near 1 (This Nautilus Biotechnology probability density function shows the probability of Nautilus Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Nautilus Biotechnology has a beta of -0.35. This indicates as returns on the benchmark increase, returns on holding Nautilus Biotechnology are expected to decrease at a much lower rate. During a bear market, however, Nautilus Biotechnology is likely to outperform the market. Additionally Nautilus Biotechnology has an alpha of 0.9253, implying that it can generate a 0.93 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Nautilus Biotechnology Price Density   
       Price  

Predictive Modules for Nautilus Biotechnology

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Nautilus Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nautilus Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.132.688.47
Details
Intrinsic
Valuation
LowRealHigh
0.112.298.08
Details
4 Analysts
Consensus
LowTargetHigh
2.282.502.78
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.17-0.15-0.14
Details

Nautilus Biotechnology Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Nautilus Biotechnology is not an exception. The market had few large corrections towards the Nautilus Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Nautilus Biotechnology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Nautilus Biotechnology within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.93
β
Beta against Dow Jones-0.35
σ
Overall volatility
0.16
Ir
Information ratio 0.14

Nautilus Biotechnology Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nautilus Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nautilus Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Nautilus Biotechnology is way too risky over 90 days horizon
Nautilus Biotechnology appears to be risky and price may revert if volatility continues
Net Loss for the year was (70.78 M) with profit before overhead, payroll, taxes, and interest of 0.
Nautilus Biotechnology currently holds about 299.34 M in cash with (59.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4.
Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures
Roughly 34.0% of the company outstanding shares are owned by corporate insiders
Latest headline from globenewswire.com: Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Nautilus Biotechnology Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nautilus Stock often depends not only on the future outlook of the current and potential Nautilus Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nautilus Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding125.4 M
Cash And Short Term Investments129.9 M

Nautilus Biotechnology Fundamentals Growth

Nautilus Stock prices reflect investors' perceptions of the future prospects and financial health of Nautilus Biotechnology, and Nautilus Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nautilus Stock performance.

About Nautilus Biotechnology Performance

Assessing Nautilus Biotechnology's fundamental ratios provides investors with valuable insights into Nautilus Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nautilus Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.34)(0.32)
Return On Capital Employed(0.31)(0.33)
Return On Assets(0.34)(0.32)
Return On Equity(0.39)(0.37)

Things to note about Nautilus Biotechnology performance evaluation

Checking the ongoing alerts about Nautilus Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nautilus Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Nautilus Biotechnology is way too risky over 90 days horizon
Nautilus Biotechnology appears to be risky and price may revert if volatility continues
Net Loss for the year was (70.78 M) with profit before overhead, payroll, taxes, and interest of 0.
Nautilus Biotechnology currently holds about 299.34 M in cash with (59.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4.
Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures
Roughly 34.0% of the company outstanding shares are owned by corporate insiders
Latest headline from globenewswire.com: Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Evaluating Nautilus Biotechnology's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Nautilus Biotechnology's stock performance include:
  • Analyzing Nautilus Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nautilus Biotechnology's stock is overvalued or undervalued compared to its peers.
  • Examining Nautilus Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Nautilus Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nautilus Biotechnology's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Nautilus Biotechnology's stock. These opinions can provide insight into Nautilus Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Nautilus Biotechnology's stock performance is not an exact science, and many factors can impact Nautilus Biotechnology's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.